Could a tiny skin shot replace harsh full-body immunotherapy for melanoma?

This early-phase study tests whether a low-dose immunotherapy injection directly into the tumor can activate the immune system as effectively as standard high-dose treatment through the veins, but with fewer side effects. About 18 adults with advanced melanoma will receive either the local injection or the usual intravenous combination therapy. Researchers will monitor immune cell changes in the blood and tumors over 13 weeks to see if the gentler approach works.